Advertisement
Research Article Free access | 10.1172/JCI2703
Diabetes Division, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
Find articles by Markees, T. in: JCI | PubMed | Google Scholar
Diabetes Division, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
Find articles by Phillips, N. in: JCI | PubMed | Google Scholar
Diabetes Division, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
Find articles by Gordon, E. in: JCI | PubMed | Google Scholar
Diabetes Division, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
Find articles by Noelle, R. in: JCI | PubMed | Google Scholar
Diabetes Division, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
Find articles by Shultz, L. in: JCI | PubMed | Google Scholar
Diabetes Division, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
Find articles by Mordes, J. in: JCI | PubMed | Google Scholar
Diabetes Division, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
Find articles by Greiner, D. in: JCI | PubMed | Google Scholar
Diabetes Division, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.
Find articles by Rossini, A. in: JCI | PubMed | Google Scholar
Published June 1, 1998 - More info
Treatment of C57BL/6 mice with one transfusion of BALB/c spleen cells and anti-CD154 (anti-CD40-ligand) antibody permits BALB/c islet grafts to survive indefinitely and BALB/c skin grafts to survive for approximately 50 d without further intervention. The protocol induces long-term allograft survival, but the mechanism is unknown. We now report: (a) addition of thymectomy to the protocol permitted skin allografts to survive for > 100 d, suggesting that graft rejection in euthymic mice results from thymic export of alloreactive T cells. (b) Clonal deletion is not the mechanism of underlying long-term graft survival, as recipient thymectomized mice were immunocompetent and harbor alloreactive T cells. (c) Induction of skin allograft acceptance initially depended on the presence of IFN-gamma, CTLA4, and CD4(+) T cells. Addition of anti-CTLA4 or anti-IFN-gamma mAb to the protocol was associated with prompt graft rejection, whereas anti-IL-4 mAb had no effect. The role of IFN-gamma was confirmed using knockout mice. (d) Graft survival was associated with the absence of IFN-gamma in the graft. (e) Long-term graft maintenance required the continued presence of CD4(+) T cells. The results suggest that, with modification, our short-term protocol may yield a procedure for the induction of long-term graft survival without prolonged immunosuppression.